Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.

The Journal of infectious diseases - 1 Mar 2004

Flandre Philippe, Descamps Diane, Joly Veronique, Meiffredy Vincent, Tamalet Catherine, Izopet Jacques, Brun-Vezinet Francoise

Abstract excerpt

Virologic studies of human immunodeficiency virus type 1-infected patients have investigated either the emergence of resistance mutations according to the treatment received (type I) or their effect on subsequent regimens (type II). Type I studies provide an estimation of the frequency distributi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Immunity, Innate

Share to Likelihood Functions

Share to Statistics, Nonparametric

Share to Survival Analysis

Share to Thymidine

Source

Identifiers

PMID: 14976604
DOI: 10.1086/381676

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-14976604-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.PMID 14976604Read ↗

Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.Semantic proximity Read ↗

Evolutionary safety of death by mutagenesisSemantic proximity Read ↗

Evolutionary safety of death by mutagenesisSemantic proximity Read ↗

Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.Semantic proximity Read ↗

Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients.Semantic proximity Read ↗

Estimating HIV evolutionary pathways and the genetic barrier to drug resistance.Semantic proximity Read ↗

Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.Semantic proximity Read ↗

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.Semantic proximity Read ↗

Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.Semantic proximity Read ↗

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.Semantic proximity Read ↗

Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort StudySemantic proximity Read ↗

Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.